Lai K N, Ho C P, Chan K W, Yan K W, Lai F M, Vallance-Owen J
Q J Med. 1985 Oct;57(222):677-88.
A combined retrospective and prospective study of 86 patients with IgA nephropathy was conducted to determine whether the level of proteinuria was a good predictive index of progressive disease. The patients fell into three groups: Group A, 31 patients with proteinuria of less than 1 g/day, Group B, 31 patients with proteinuria of 1 to 3.5 g/day; and Group C, 24 patients with proteinuria of more than 3.5 g/day. The groups are comparable in age of presentation, sex ratio, and duration of study and showed no difference in serum creatinine levels, creatinine clearance, incidence of hypertension or incidence of impaired renal function. Compared with the patients in the other groups, those in Group C did not have increased incidence of progressive disease. Nevertheless, they have a higher incidence of nephrotic syndrome (p less than 0.001), a lower incidence of macroscopic haematuria (p less than 0.05), lower serum albumin (p less than 0.05) and heavier proteinuria (p less than 0.01). Severity of proteinuria had no significant correlation with the severity of renal histopathologic changes. Clinical observations divided the 24 patients with nephrotic range proteinuria into three well-defined groups with different prognoses. Six patients had progressive disease with decreasing proteinuria. Five of these remained hypertensive and their initial renal biopsy showed advanced pathologic changes. Thirteen patients had persistent proteinuria although the renal function remained unchanged. Three of these were treated with steroid but failed to respond, and their renal histopathologic changes were usually moderate. The remaining five patients showed good response to steroid treatment although two became steroid-dependent. Their renal histopathology showed mild alteration. Our findings suggest that severe proteinuria in IgA nephropathy does not inevitably indicate a poor prognosis.
对86例IgA肾病患者进行了一项回顾性与前瞻性相结合的研究,以确定蛋白尿水平是否是疾病进展的良好预测指标。患者分为三组:A组,31例蛋白尿少于1g/天;B组,31例蛋白尿为1至3.5g/天;C组,24例蛋白尿超过3.5g/天。三组在就诊年龄、性别比和研究持续时间方面具有可比性,血清肌酐水平、肌酐清除率、高血压发病率或肾功能受损发病率无差异。与其他组患者相比,C组患者疾病进展的发病率并未增加。然而,他们的肾病综合征发病率较高(p<0.001),肉眼血尿发病率较低(p<0.05),血清白蛋白较低(p<0.05),蛋白尿较重(p<0.01)。蛋白尿严重程度与肾脏组织病理学改变的严重程度无显著相关性。临床观察将24例肾病范围蛋白尿患者分为三个预后不同的明确组。6例患者疾病进展且蛋白尿减少。其中5例仍有高血压,其初始肾活检显示有晚期病理改变。13例患者蛋白尿持续存在,尽管肾功能保持不变。其中3例接受类固醇治疗但无反应,其肾脏组织病理学改变通常为中度。其余5例患者对类固醇治疗反应良好,尽管2例出现类固醇依赖。他们的肾脏组织病理学显示轻度改变。我们的研究结果表明,IgA肾病中的严重蛋白尿并不必然预示预后不良。